Trial Profile

WT1 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with WT1-specific TCR gene"

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WT1 TCR-transduced T cells-Takara Bio (Primary) ; Montanide ISA-51
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

05 Nov 2016 Status changed from suspended to discontinued.
06 May 2016 Status changed from recruiting to suspended.
07 May 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com